# Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease

Study · id `cardio:ct-nct05373004` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05373004](<https://clinicaltrials.gov/study/NCT05373004>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05373004

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 212 participants.

## Technical summary

Registry record NCT05373004. Randomized; double masking; primary purpose prevention. Start 2023-03 (anticipated); primary completion 2024-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 212 participants (planned count; ClinicalTrials.gov record NCT05373004, source copy `cardio:ctgov-nct05373004-2022-05-13`, retrieved 2026-10-26)
- Planned start: 2023-03 (anticipated) (ClinicalTrials.gov record NCT05373004, source copy `cardio:ctgov-nct05373004-2022-05-13`, retrieved 2026-10-26)
- Primary completion: 2024-03 (anticipated) (ClinicalTrials.gov record NCT05373004, source copy `cardio:ctgov-nct05373004-2022-05-13`, retrieved 2026-10-26)
- Completion: 2024-05 (anticipated) (ClinicalTrials.gov record NCT05373004, source copy `cardio:ctgov-nct05373004-2022-05-13`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05373004-2022-05-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
- Acronym: SGLT2i VS ACEi
- Condition: Diabetic Nephropathy Type 2
- Intervention (Drug): Empagliflozin 25 MG
- Intervention (Drug): Enalapril Maleate 20 mg
- Lead sponsor: Omar Tarek Elfarargi
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 45c78968da8945757344bf9de8bd372b57736d5fc32774e72df8a354d6f7469e
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
